Macrolides are associated with a better survival rate in patients hospitalized with community-acquired but not healthcare-associated pneumonia

Surgical Infections

Volumn 15, Issue 3, 2014, Pages 283-289

  Mcevoy, Colleen ^a   Micek, Scott T ^b   Reichley, Richard M ^b   Kan, Jason ^b   Hoban, Alex ^a   Hoffmann, Justin ^c   Shorr, Andrew F ^d   Kollef, Marin H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

^c ST LOUIS COLLEGE OF PHARMACY   (United States)

^d WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; MACROLIDE; ANTIINFECTIVE AGENT;

ACHROMOBACTER; ACINETOBACTER; ADOLESCENT; ADULT; AGED; ARTICLE; BURKHOLDERIA; CHARLSON COMORBIDITY INDEX; CITROBACTER; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DISEASE SEVERITY; EMERGENCY CARE; END STAGE LIVER DISEASE; ENTEROBACTER; ENTEROBACTERIACEAE; FEMALE; HAEMOPHILUS; HAEMOPHILUS INFLUENZAE; HUMAN; KLEBSIELLA PNEUMONIAE; LEGIONELLA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MORAXELLA; MORGANELLA; MORTALITY; MYCOPLASMA PNEUMONIAE; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; PROTEUS; PROVIDENCIA; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; SERRATIA MARCESCENS; STENOTROPHOMONAS MALTOPHILIA; VERY ELDERLY; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; MIDDLE AGED; PNEUMONIA; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; FEMALE; HUMANS; MACROLIDES; MALE; MIDDLE AGED; PNEUMONIA; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903199584     PISSN: 10962964     EISSN: 15578674     Source Type: Journal    
DOI: 10.1089/sur.2013.076     Document Type: Article

References (26)

1. File TM Jr, Marrie TJ. Burden of community-Acquired pneumonia in North American adults. Postgrad Med 2010; 122:130-141.
2. Dharmarajan K, Hsieh AF, Lin Z, et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA 2013;309:355-363.
3. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of communityacquired pneumonia in adults. Clin Infect Dis 2007; 44(Suppl 2):S27-S72. (Pubitemid 46290553)
4. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003;36:389-395.
5. Metersky ML, Ma A, Houck PM, Bratzler DW. Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones. Chest 2007;131:466-473. (Pubitemid 46280407)
6. Restrepo MI, Mortensen EM, Waterer GW, et al. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 2009;33:153-159.
7. Asadi L, Sligl WI, Eurich DT, et al. Macrolide-based regimens and mortality in hospitalized patients with communityacquired pneumonia: A systematic review and meta-Analysis. Clin Infect Dis 2012;55:371-380.
8. Kollef MH, Morrow LE, Baughman RP, et al. Health careassociated pneumonia (HCAP): A critical appraisal to improve identification, management, and outcomes. Proceedings of the HCAP Summit. Clin Infect Dis 2008; 46(Suppl 4):S296-S334.
9. Eliakim-Raz N, Robenshtok E, Shefet D, et al. Empiric antibiotic coverage of atypical pathogens for communityacquired pneumonia in hospitalized adults. Cochrane Database Syst Rev 2012;9:CD004418.
10. Asadi L, Eurich DT, Gamble JM, et al. Impact of guidelineconcordant antibiotics and macrolide/b-lactam combinations in 3203 patients hospitalized with pneumonia: Prospective cohort study. Clin Microbiol Infect 2013;19: 257-264.
11. Martin-Loeches I, Bermejo-Martin JF, Valles J, et al. Macrolide-based regimens in absence of bacterial coinfection in critically ill H1N1 patients with primary viral pneumonia. Intensive Care Med 2013;39:693-702.
12. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:689-698.
13. Saiman L, Anstead M, Mayer-Hamblett N, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: A randomized controlled trial. JAMA 2010;303:1707-1715.
14. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: A randomized controlled trial. JAMA 2003;290:1749-1756. (Pubitemid 37430625)
15. Jain R, Hachem RR, Morrell MR, et al. Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome. J Heart Lung Transplant 2010;29:531-537.
16. Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): A multicentre randomised double-blind placebocontrolled trial. Thorax 2013;68:322-329.
17. Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2006;174:566-570. (Pubitemid 44330550)
18. Spagnolo P, Fabbri LM, Bush A. Long-Term macrolide treatment for chronic respiratory disease. Eur Respir J 2012 (Epub ahead of print).
19. Low DE. What is the relevance of antimicrobial resistance on the outcome of community-Acquired pneumonia caused by Streptococcus pneumoniae? (Should macrolide monotherapy be used for mild pneumoniä). Infect Dis Clin North Am 2013;27:87-97.
20. Buyck JM, Plesiat P, Traore H, et al. Increased susceptibility of Pseudomonas aeruginosa to macrolides and ketolides in eukaryotic cell culture media and biological fluids due to decreased expression of oprM and increased outer-membrane permeability. Clin Infect Dis 2012;55: 534-542.
21. Blaschke AJ. Interpreting assays for the detection of Streptococcus pneumoniae. Clin Infect Dis 2011;52(Suppl 4):S331-S337.
22. Labelle AJ, Arnold H, Reichley RM, et al. A comparison of culture-positive and culture-negative health-care-Associated pneumonia. Chest 2010;137:1130-1137.
23. Ewig S, Welte T, Torres A. Is healthcare-Associated pneumonia a distinct entity needing specific therapy? Curr Opin Infect Dis 2012;25:166-175.
24. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-Acquired, ventilator-Associated, and healthcare-Associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
25. Costelloe C, Metcalfe C, Lovering A, et al. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: Systematic review and meta-Analysis. BMJ 2010;340:c2096.
26. El Solh AA, Pietrantoni C, Bhat A, et al. Indicators of potentially drug-resistant bacteria in severe nursing homeacquired pneumonia. Clin Infect Dis 2004;39:474-480. (Pubitemid 39120921)